Search results
Results from the WOW.Com Content Network
For premium support please call: 800-290-4726 more ways to reach us
The underwhelming share price performance of ImmunoGen, Inc. ( NASDAQ:IMGN ) in the past three years would have...
ImmunoGen, Inc. was a biotechnology company focused on the development of antibody-drug conjugate (ADC) therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and was headquartered in Waltham, Massachusetts.
ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AbbVie has offered $31.26 per share in cash, representing a premium of 94.6% to Immuogen stock's last close. Immunogen's shares surged 82% to a near 23-year high of $29.34 in early trading.
ImmunoGen (IMGN) delivered earnings and revenue surprises of 52.38% and 56.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you buy shares in a... Despite shrinking by US$77m in the past week, ImmunoGen (NASDAQ:IMGN ...
ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.